Evidence map›Paper›PMID 33333978›Full record

ArticleInternational journal of molecular sciences2020

In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells.

Ilham M Alshiraihi, Dillon K Jarrell, Zeyad Arhouma, Kelly N Hassell, Jaelyn Montgomery, Alyssa Padilla, Hend M Ibrahim, Debbie C Crans, Takamitsu A Kato, Mark A Brown

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Assessing DNA Damage Through the Cell Cycle Using Flow Cytometry.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Ilham M AlshiraihiCell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523-1005, USA.ORCID 0000-0001-8061-8350
Dillon K JarrellDepartment of Bioengineering, University of Colorado Anschutz Medical Campus, Aurora, CO 80045-7109, USA.
Zeyad ArhoumaCell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523-1005, USA.
Kelly N HassellCell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523-1005, USA.
Jaelyn MontgomeryDepartment of Biomedical Sciences, Colorado State University, Fort Collins, CO 80523-1617, USA.
Alyssa PadillaDepartment of Biomedical Sciences, Colorado State University, Fort Collins, CO 80523-1617, USA.
Hend M IbrahimDepartment of Medical Biochemistry, Zagazig University, Zagazig 44511, Egypt.
Debbie C CransCell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523-1005, USA.
Takamitsu A KatoCell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523-1005, USA.ORCID 0000-0001-7792-3450
Mark A BrownCell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80523-1005, USA.
Colorado State University · USColorado School of Public Health · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Tabuk · SAZagazig University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SMYD3 is a lysine methyltransferase that regulates the expression of over 80 genes and is required for the uncontrolled proliferation of most breast, colorectal, and hepatocellular carcinomas. The elimination of SMYD3 restores normal expression patterns of these genes and halts aberrant cell proliferation, making it a promising target for small molecule inhibition. In this study, we sought to establish a proof of concept for our in silico/in vitro hit-to-lead enzyme inhibitor development platform and to identify a lead small molecule candidate for SMYD3 inhibition. We used Schrodinger

Indexed as

Drug DiscoveryMolecular Docking SimulationMolecular Dynamics SimulationApoptosisBreast NeoplasmsCell Line, TumorCell SurvivalFemaleHistone Deacetylase InhibitorsHistone-Lysine N-MethyltransferaseHumansMolecular StructureStructure-Activity RelationshipHistone Deacetylase InhibitorsHistone-Lysine N-MethyltransferaseSMYD3 protein, humanapoptosisbreast cancercell cyclecell proliferationhit-to-leadInhibitor-4in silico drug developmentmethyltransferaseSMYD3

Identifiers

PMID33333978
PMCPMC7765450
OpenAlexW3112509679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.